Johnson & Johnson (JNJ) 102.17 $JNJ
Jim Cramer's Top Stock Picks: MWV MHR JNJ ADS
at The Street - 6 mins ago
Cramer has some advice for Johnson & Johnson and thinks Alliance Data Systems is reviving retail.
Jim Cramer's 'Mad Money' Recap: Individual Stocks Rule
at The Street - Mon Jun 02, 7:16PM CDT
Cramer sounds off against the professional money managers who trade the market like it's merely a basket of commodities.
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Final Glance: Pharmaceuticals companies
AP - Mon Jun 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Mon Jun 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Mon Jun 02, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Mon Jun 02, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
7 Stocks That Will Lift the Dow Jones Industrial Average to New High
at The Street - Mon Jun 02, 11:33AM CDT
Du Pont, Disney, Intel, Johnson & Johnson, Microsoft, Travelers and Exxon Mobil are likely to lift the Dow Jones Industrial Average to a new all-time high in June.
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 11:10AM CDT
Pharmacyclics (PCYC) announced positive late stage data on Imbruvica.
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $102.17
Comtex SmarTrend(R) - Mon Jun 02, 10:42AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.18 today and have reached the first resistance level of $101.82. Analysts will be watching for a cross of the next upside pivot targets of $102.17 and $103.16.
Early Glance: Pharmaceuticals companies
AP - Mon Jun 02, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Mon Jun 02, 9:30AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Cosmetic Product Companies Look to Expand Operations - Company Enters Agreement with Major Distributor for Sale of Beauty & Cosmetic Products in North America
PR Newswire - Mon Jun 02, 7:30AM CDT
Consumer goods companies specializing in cosmetics take steps to increase production and value with partnerships and other developments: Verde Media Group Inc. (OTC: VMGI), Elizabeth Arden, Inc. (NASDAQ: RDEN), Avon Products Inc. (NYSE: AVP), The Procter & Gamble Company (NYSE: PG), Johnson & Johnson (NYSE: JNJ) and Colgate-Palmolive Co. (NYSE: CL)
Celladon Corporation Appoints Industry Veteran Paul Cleveland as President and Chief Financial Officer
GlobeNewswire - Mon Jun 02, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has appointed Paul Cleveland President and Chief Financial Officer.
3 Stocks to Watch in the Changing Landscape of ADHD Drugs
Leo Sun, The Motley Fool - Motley Fool - Sun Jun 01, 10:05AM CDT
A March report from pharmacy benefit manager Express Scripts revealed that U.S. prescriptions for adult attention deficit hyperactive disorder drugs rose from 1.7 million in 2008 to 2.6 million in 2012 -- a 53% increase. That study, which analyzed...
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
Should Johnson & Johnson Join the Buyout Boom?
Dan Carroll, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
Mergers and acquisitions have been all the rage in health care in 2014. Big pharma's taken over the spotlight recently, but medical device giants have joined in the game recently, and now major orthopedics and spine device maker Smith & Nephew ...
Update on Bayer's Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 5:20PM CDT
Bayer (BAYRY) announced that it submitted a Marketing Authorization Application for Xarelto in Japan.
Jim Cramer's Top Stock Picks: MWV MHR JNJ ADS
at The Street - 6 mins ago
Cramer has some advice for Johnson & Johnson and thinks Alliance Data Systems is reviving retail.
Jim Cramer's 'Mad Money' Recap: Individual Stocks Rule
at The Street - Mon Jun 02, 7:16PM CDT
Cramer sounds off against the professional money managers who trade the market like it's merely a basket of commodities.
3 Reasons Celgene Is a Buy
Cory Renauer, The Motley Fool - Motley Fool - Mon Jun 02, 5:30PM CDT
Celgene was the subject of a recent downgrade from "overweight" to "neutral" by JPMorgan. Analysts didn't cite new concerns, but that won't stop media from speculating. In the face of uncertainty now is a great time to revisit the bull argument for...
Final Glance: Pharmaceuticals companies
AP - Mon Jun 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Final Glance: Medical Devices companies
AP - Mon Jun 02, 5:02PM CDT
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
Midday Glance: Pharmaceuticals companies
AP - Mon Jun 02, 12:21PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Midday Glance: Medical Devices companies
AP - Mon Jun 02, 12:21PM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
7 Stocks That Will Lift the Dow Jones Industrial Average to New High
at The Street - Mon Jun 02, 11:33AM CDT
Du Pont, Disney, Intel, Johnson & Johnson, Microsoft, Travelers and Exxon Mobil are likely to lift the Dow Jones Industrial Average to a new all-time high in June.
Encouraging Data on Pharmacyclics/J&J Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 02, 11:10AM CDT
Pharmacyclics (PCYC) announced positive late stage data on Imbruvica.
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $102.17
Comtex SmarTrend(R) - Mon Jun 02, 10:42AM CDT
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.18 today and have reached the first resistance level of $101.82. Analysts will be watching for a cross of the next upside pivot targets of $102.17 and $103.16.
Early Glance: Pharmaceuticals companies
AP - Mon Jun 02, 9:30AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Early Glance: Medical Devices companies
AP - Mon Jun 02, 9:30AM CDT
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
Cosmetic Product Companies Look to Expand Operations - Company Enters Agreement with Major Distributor for Sale of Beauty & Cosmetic Products in North America
PR Newswire - Mon Jun 02, 7:30AM CDT
Consumer goods companies specializing in cosmetics take steps to increase production and value with partnerships and other developments: Verde Media Group Inc. (OTC: VMGI), Elizabeth Arden, Inc. (NASDAQ: RDEN), Avon Products Inc. (NYSE: AVP), The Procter & Gamble Company (NYSE: PG), Johnson & Johnson (NYSE: JNJ) and Colgate-Palmolive Co. (NYSE: CL)
Celladon Corporation Appoints Industry Veteran Paul Cleveland as President and Chief Financial Officer
GlobeNewswire - Mon Jun 02, 6:00AM CDT
Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, today announced it has appointed Paul Cleveland President and Chief Financial Officer.
3 Stocks to Watch in the Changing Landscape of ADHD Drugs
Leo Sun, The Motley Fool - Motley Fool - Sun Jun 01, 10:05AM CDT
A March report from pharmacy benefit manager Express Scripts revealed that U.S. prescriptions for adult attention deficit hyperactive disorder drugs rose from 1.7 million in 2008 to 2.6 million in 2012 -- a 53% increase. That study, which analyzed...
Pharmacyclics' Imbruvica Extends Survival in Elderly Leukemia Patients
at The Street - Sat May 31, 6:35AM CDT
Pharmacyclics and Johnson & Johnson's blood-cancer drug Imbruvica reduced the risk of dying by 57% compared to GlaxoSmithKline's Arzerra when used to treat elderly patients with relapsed chronic lymphocytic leukemia, according to results from a phase...
Should Johnson & Johnson Join the Buyout Boom?
Dan Carroll, The Motley Fool - Motley Fool - Fri May 30, 5:30PM CDT
Mergers and acquisitions have been all the rage in health care in 2014. Big pharma's taken over the spotlight recently, but medical device giants have joined in the game recently, and now major orthopedics and spine device maker Smith & Nephew ...
Update on Bayer's Xarelto - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 30, 5:20PM CDT
Bayer (BAYRY) announced that it submitted a Marketing Authorization Application for Xarelto in Japan.
